Disease: HBeAg negative chronic hepatitis B (hepatitis B minor triplet) Gao Yufeng, Department of Hepatology, Second Affiliated Hospital of Anhui Medical University Description: Male, 25 years old; father passed away due to liver cancer, good family economic condition. 2010, after father found liver cancer, physical examination HBsAg positive, hepatitis B minor triplet, liver function mildly abnormal, HBV DNA positive, given entecavir antiviral therapy, treatment During the treatment period, liver function remained normal and HBV DNA was negative. However, after her father died of liver cancer in 2012, the patient was very worried that she might develop liver cancer later. Treatment expectation: expect to cure hepatitis B and reduce the risk of liver cancer Examination and medication: – Diagnosis: HBeAg-negative chronic hepatitis B. – History: HBeAg-negative chronic hepatitis B diagnosed in October 2010; started on entecavir antiviral therapy until December 2012. – Examination: virology: HBV DNA <500copies/mL; serology: HBsAg(+), HBsAb(-), HBeAg(-), HBeAb(+); biochemistry: normal ALT and AST. Treatment course: The patient was a young male, previously given entecavir antiviral therapy for more than 2 years, with non-maternal-to-child transmission, HBsAg down to a low level (783 IU/ml), HBeAg negative, and a strong desire to obtain further therapeutic effects. After administration of pegylated interferon-2a, HBV DNA was maintained negative with normal liver function on recheck every 3 months; HBsAg quantification continued to decrease; and HBsAg clearance occurred after 1 year (i.e., 48 weeks) of treatment. Considering the patient's strong desire for cure and the fact that HBsAg had already converted to negative at 1 year of combined Pyroxin treatment, treatment with pegylated interferon-2a was continued to improve the chances of achieving HBsAg seroconversion, and the patient continued treatment until serological conversion of HBsAg occurred at 72 weeks. No significant adverse effects were seen during the treatment period. Expert summary: Current studies have shown that nucleoside treated patients with HBsAg levels less than 1000 IU/ml given in combination with interferon have a higher probability of serological conversion of HBsAg to meet the criteria for drug discontinuation. During the treatment of nucleoside treated patients with combined long-acting interferon, the magnitude of the decrease in HBsAg and HBeAg quantification is the main criterion for judging the efficacy, and patients with a more significant decrease in HBsAg quantification during treatment are expected to achieve good results.